Embla Medical Hf. Reiterates Earnings Guidance for the Full Year 2025

Published on 04/29/2025 at 01:00

S&P Capital IQ

-0.31%

Embla Medical hf. reiterated earnings guidance for the full year 2025. For the period, the company reiterates guidance for the full year of 5-8% organic sales growth.

Latest news about Embla Medical hf.

Embla Medical to Buy Majority Stake in Germany's Streifeneder	Jul. 17	MT
Embla Medical to invest in majority stake in Streifeneder Ortho.Production GmbH	Jul. 17	RE
DNB Carnegie Downgrades Embla to Hold (Buy), Reiterates Target Price of 35.5 Danish Kroner - BN	Jul. 17	FW
Danske Bank Raises Target Price for Össur to 28 Danish Kroner, Reiterates Sell Rating - BN	Jul. 01	FW
Embla Medical hf., Q1 2025 Earnings Call, Apr 29, 2025	Jun. 11
Embla Medical: 2025 Outlook Unchanged	Apr. 29	RE
Tranche Update on Embla Medical hf.'s Equity Buyback Plan announced on February 7, 2025.	Apr. 29	CI
Embla Medical hf. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 29	CI
Embla Medical Hf. Reiterates Earnings Guidance for the Full Year 2025	Apr. 29	CI
Embla Medical Hf. Appoints Conal Harte as Executive Vice President of Patient Care	Apr. 29	CI
Danske Bank downgrades Össur to sell (hold), target price DKK 25 - BN	Apr. 08	FW
BASF?s Cellasto and Össur Collaborate to Enhance Performance in Foot Prosthesis	Apr. 02	CI
Embla Medical Appoints André Rocha Executive Vice President of Research and Development	Feb. 24	CI
Embla Medical to Launch Up to $10 Million Buyback Program	Feb. 07	MT
Embla Medical hf. announces an Equity Buyback for 2,000,000 shares.	Feb. 07	CI
Embla Medical hf. authorizes a Buyback Plan.	Feb. 06	CI
Embla Medical hf., Q4 2024 Earnings Call, Feb 05, 2025	Feb. 05
Embla Medical hf. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Feb. 05	CI
Embla Medical Hf Says Guidance For 2025 Of 5-8% Organic Sales Growth And 20-21% Ebitda Margin	Feb. 05	RE
Embla Medical hf. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	Feb. 05	CI
Embla Medical Announces Departure of Hildur Einarsdóttir, EVP R&D	Nov. 06	CI
Embla Medical Hf. Reiterates Guidance for Full Year 2024	24-10-22	CI
Embla Medical hf., Q3 2024 Earnings Call, Oct 22, 2024	24-10-22
Embla Medical hf. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	24-10-22	CI
Vitrolife AB Announces Election Committee Appointments	24-10-04	CI